Novartis data underscore pioneering scientific innovation in hematology and oncology at ASH and SABCS

Novartis data underscore pioneering scientific innovation in hematology and oncology at ASH and SABCS
arcticnovartis

  • Positive results from ianalumab pivotal Phase III trial in ITP patients previously treated with corticosteroids to be presented as late-breaker
  • Scemblix data across clinical and real-world settings offer new evidence informing CML care amid evolving patient needs
  • 96-week pelabresib Phase III data represent longest follow-up of first-line myelofibrosis patients in randomized combination trial
/by

Novartis receives FDA approval for Itvisma®, the only gene replacement therapy for children two years and older, teens, and adults with spinal muscular atrophy (SMA)

Novartis receives FDA approval for Itvisma®, the only gene replacement therapy for children two years and older, teens, and adults with spinal muscular atrophy (SMA)
arcticnovartis

Ad hoc announcement pursuant to Art. 53 LR

/by